Erasca Inc (ERAS : NASDAQ)
Common Stock
$14.05
USD
+0.00 (%)
Last updated: 2026-11-03
Follow ERAS
ERAS
Erasca Inc
WealthAwesomePerformance
1 Day
-2.09%
1 Week
-6.27%
1 Month
-4.68%
YTD
+0.50%
Key Statistics
Market Cap
$4.91B
52W High
$24.28
52W Low
$2.10
P/E Ratio
-
50 Day MA
$15.48
200 Day MA
$15.00
Beta
0.65
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/3/2026 | $14.30 | $15.00 | $14.06 | $14.64 | $14.64 | 3,798,381 |
| 11/2/2026 | $14.76 | $15.38 | $13.72 | $14.05 | $14.05 | 4,388,520 |
| 10/30/2026 | $14.66 | $15.01 | $14.04 | $14.35 | $14.35 | 3,749,200 |
| 10/29/2026 | $15.11 | $15.45 | $14.66 | $14.98 | $14.98 | 2,250,279 |
| 10/28/2026 | $14.90 | $15.32 | $14.45 | $15.12 | $15.12 | 3,385,923 |
| 10/27/2026 | $14.95 | $15.26 | $14.72 | $15.22 | $15.22 | 5,085,199 |
| 10/26/2026 | $14.58 | $15.47 | $14.54 | $14.99 | $14.99 | 6,466,114 |
| 10/23/2026 | $13.99 | $14.45 | $13.44 | $14.39 | $14.39 | 3,499,900 |
| 10/22/2026 | $14.22 | $14.64 | $13.81 | $14.04 | $14.04 | 2,296,064 |
| 10/21/2026 | $14.82 | $15.05 | $14.38 | $14.49 | $14.49 | 3,843,404 |
Analyst Price Targets
Based on 9 analysts covering ERAS · as of Oct 5, 2026
Wall Street analysts forecast ERAS stock price to rise 71.6% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
US$24.11
+71.6% Upside
Current Price
US$14.05
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ERAS's historical volatility
30-Day Vol
67.9%
Annualized
90-Day Vol
60.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$12.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$13.79 | US$10.91 – US$17.43 |
| 60 trading days | US$13.00 | US$9.33 – US$18.10 |
| 90 trading days | US$12.25 | US$8.16 – US$18.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-147.74M
- Profit Margin
- 0.00%
- ROE (TTM)
- -78.25%
- EPS (Diluted)
- -0.95
- Book Value
- 1.16
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About ERAS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| VCIG | VCI Global Limited Ordinary Share | $8.16 | +4728.40% |
| RETO | ReTo Eco-Solutions Inc | $4.16 | +647.26% |
| BJDX | Bluejay Diagnostics Inc | $2.12 | +281.02% |
| INO | Inovio Pharmaceuticals Inc | $1.89 | +215.00% |
| CLRO | ClearOne Inc | $5.65 | +65.69% |
| INLF | INLIF LIMITED Ordinary Shares | $0.29 | +56.76% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.06 | +55.50% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $2.85 | +52.41% |
ERAS.US news timeline
1 article covering ERAS.US, most recent first
Latest